Preliminary evaluation of arginine deiminase activity of indigenous bacterial strains for suitable chemotherapeutic applications
Biocatalysis and Agricultural Biotechnology, ISSN: 1878-8181, Vol: 12, Page: 66-77
2017
- 7Citations
- 18Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Cancer is one of the most detrimental disease affects significant segment of human population. Arginine deiminase (ADI) is an anticancer enzyme used in chemotherapy of certain kinds of arginine auxotrophic cancers. However, high antigenicity, shorter serum half-life and low proteolytic tolerance are the major therapeutic limitations which dramatically hampers clinical efficacy of ADI. In the present study, 151 bacterial strains were screened and among them 40 bacterial strains were recorded as ADI positive strains by screening on M-9 medium containing phenol red. To confirm the ADI activity, positive strains were further screened on M-9 medium incorporated with bromocresol purple and bromothymol blue as pH indicators. By quantification of ADI activity, among 40 ADI positive strains, eight strains were considered as potential ADI producers. They exhibited ADI activity in the range of 2.91 IU ml −1 to 5.56 IU ml −1. The crude ADI obtained from these strains were evaluated for in vitro serum half-life, proteolytic tolerance and anticancer activity. Among 8 strains, crude ADI prepared from PS2 and FB1 showed significant in vitro serum half-life, strong proteolytic tolerance and potent anticancer activity. On the basis of morphological, cultural, biochemical characteristics and 16 S rRNA gene sequencing these bacterial strains were identified as Pseudomonas aeruginosa PS2 and Sphingobacterium sp. FB1. From this study, we conclude that ADI from identified bacterial strains could serve as potent anticancer agent. However, more in depth studies are required for strengthening the current findings, which are underway.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1878818117302165; http://dx.doi.org/10.1016/j.bcab.2017.09.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85029285462&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1878818117302165; https://dx.doi.org/10.1016/j.bcab.2017.09.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know